Promoter hypermethylation of CDKN2A, MGMT, MLH1, and DAPK genes in laryngeal squamous cell carcinoma and their associations with clinical profiles of the patients

Head and Neck

Volumn 36, Issue 8, 2014, Pages 1103-1108

  Pierini, Stefano ^a   Jordanov, Stanislav H ^a   Mitkova, Atanaska V ^a   Chalakov, Ivan J ^a   Melnicharov, Mincho B ^a   Kunev, Kuncho V ^a   Mitev, Vanio I ^a   Kaneva, Radka P ^a   Goranova, Teodora E ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

CDKN2A; laryngeal carcinoma; lymph node metastases; MLH1; promoter hypermethylation

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH ASSOCIATED PROTEIN KINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN MLH1; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CORRELATIONAL STUDY; DNA METHYLATION; FEMALE; GENE INACTIVATION; GENETIC ASSOCIATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; LARYNX SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SMOKING; AGED; BULGARIA; GENETICS; LARYNX TUMOR; MIDDLE AGED; PATHOLOGY; PROMOTER REGION; SQUAMOUS CELL CARCINOMA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; BULGARIA; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DEATH-ASSOCIATED PROTEIN KINASES; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PREVALENCE; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84904244652     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23413     Document Type: Article

References (41)

1. Wong TS, Gao W, Li ZH, Chan JY, Ho WK,. Epigenetic dysregulation in laryngeal squamous cell carcinoma. J Oncol 2012; 2012: 739461.
2. Crowe DL, Hacia JG, Hsieh CL, Sinha UK, Rice H,. Molecular pathology of head and neck cancer. Histol Histopathol 2002; 17: 909-914.
3. Papadimitrakopoulou VA,. Carcinogenesis of head and neck cancer and the role of chemoprevention in its reversal. Curr Opin Oncol 2000; 12: 240-245.
4. Altieri A, Bosetti C, Gallus S, et al. Wine, beer and spirits and risk of oral and pharyngeal cancer: a case-control study from Italy and Switzerland. Oral Oncol 2004; 40: 904-909.
5. Kruman II, Henderson GI, Bergeson SE,. DNA damage and neurotoxicity of chronic alcohol abuse. Exp Biol Med (Maywood) 2012; 237: 740-747.
6. Soma T, Kaganoi J, Kawabe A, Kondo K, Imamura M, Shimada Y,. Nicotine induces the fragile histidine triad methylation in human esophageal squamous epithelial cells. Int J Cancer 2006; 119: 1023-1027.
7. Maier H, Dietz A, Gewelke U, Heller WD, Weidauer H,. Tobacco and alcohol and the risk of head and neck cancer. Clin Investig 1992; 70: 320-327.
8. Puri SK, Si L, Fan CY, Hanna E,. Aberrant promoter hypermethylation of multiple genes in head and neck squamous cell carcinoma. Am J Otolaryngol 2005; 26: 12-17.
9. Sasiadek MM, Stembalska-Kozlowska A, Smigiel R, Ramsey D, Kayademir T, Blin N,. Impairment of MLH1 and CDKN2A in oncogenesis of laryngeal cancer. Br J Cancer 2004; 90: 1594-1599.
10. Gleich LL, Salamone FN,. Molecular genetics of head and neck cancer. Cancer Control 2002; 9: 369-378.
11. Loyo M, Pai SI,. The molecular genetics of laryngeal cancer. Otolaryngol Clin North Am 2008; 41: 657-672.
12. Mäkitie AA, Monni O,. Molecular profiling of laryngeal cancer. Expert Rev Anticancer Ther 2009; 9: 1251-1260.
13. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT,. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 2002; 21: 4231-4236.
14. Paluszczak J, Misiak P, Wierzbicka M, Woźniak A, Baer-Dubowska W,. Frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT in laryngeal squamous cell carcinomas and adjacent normal mucosa. Oral Oncol 2011; 47: 104-107.
15. Liu K, Huang H, Mukunyadzi P, Suen JY, Hanna E, Fan CY,. Promoter hypermethylation: an important epigenetic mechanism for hMLH1 gene inactivation in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2002; 126: 548-553.
16. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
17. Wong TS, Chang HW, Tang KC, et al. High frequency of promoter hypermethylation of the death-associated protein-kinase gene in nasopharyngeal carcinoma and its detection in the peripheral blood of patients. Clin Cancer Res 2002; 8: 433-437.
18. Dikshit RP, Gillio-Tos A, Brennan P, et al. Hypermethylation, risk factors, clinical characteristics, and survival in 235 patients with laryngeal and hypopharyngeal cancers. Cancer 2007; 110: 1745-1751.
19. Calmon MF, Colombo J, Carvalho F, et al. Methylation profile of genes CDKN2A (p14 and p16), DAPK1, CDH1, and ADAM23 in head and neck cancer. Cancer Genet Cytogenet 2007; 173: 31-37.
20. Taioli E, Ragin C, Wang XH, et al. Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation. BMC Cancer 2009; 9: 354.
21. Steinmann K, Sandner A, Schagdarsurengin U, Dammann RH,. Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep 2009; 22: 1519-1526.
22. Bennett KL, Karpenko M, Lin MT, et al. Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Res 2008; 68: 4494-4499.
23. Righini CA, de Fraipont F, Reyt E, Favrot MC,. [Aberrant methylation of tumor suppressor genes in head and neck squamous cell carcinoma: is it clinically relevant?]. [Article in French] Bull Cancer 2007; 94: 191-197.
24. Nan HM, Song YJ, Yun HY, Park JS, Kim H,. Effects of dietary intake and genetic factors on hypermethylation of the hMLH1 gene promoter in gastric cancer. World J Gastroenterol 2005; 11: 3834-3841.
25. Su PF, Huang WL, Wu HT, Wu CH, Liu TY, Kao SY,. p16(INK4A) promoter hypermethylation is associated with invasiveness and prognosis of oral squamous cell carcinoma in an age-dependent manner. Oral Oncol 2010; 46: 734-739.
26. Sanchez-Cespedes M, Esteller M, Wu L, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000; 60: 892-895.
27. Supic̈ G, Kozomara R, Brankovic̈-Magic̈ M, Jovic̈ N, Magic̈ Z,. Gene hypermethylation in tumor tissue of advanced oral squamous cell carcinoma patients. Oral Oncol 2009; 45: 1051-1057.
28. Gay LJ, Arends MJ, Mitrou PN, et al. MLH1 promoter methylation, diet, and lifestyle factors in mismatch repair deficient colorectal cancer patients from EPIC-Norfolk. Nutr Cancer 2011; 63: 1000-1010.
29. Koscielny S, Dahse R, Ernst G, von Eggeling F,. The prognostic relevance of p16 inactivation in head and neck cancer. ORL J Otorhinolaryngol Relat Spec 2007; 69: 30-36.
30. Wojdacz TK, Dobrovic A,. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 2007; 35: e41.
31. Liu W, Guan M, Su B, et al. Rapid determination of AKAP12 promoter methylation levels in peripheral blood using methylation-sensitive high resolution melting (MS-HRM) analysis: application in colorectal cancer. Clin Chim Acta 2010; 411: 940-946.
32. Wojdacz TK, Hansen LL, Dobrovic A,. A new approach to primer design for the control of PCR bias in methylation studies. BMC Res Notes 2008; 1: 54.
33. Candiloro IL, Mikeska T, Hokland P, Dobrovic A,. Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene. Epigenetics Chromatin 2008; 1: 7.
34. Rosas SL, Koch W, da Costa Carvalho MG, et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001; 61: 939-942.
35. Agnese V, Corsale S, Calò V, et al. Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. Ann Oncol 2006; 17 Suppl 7: vii137-vii141.
36. Demokan S, Suoglu Y, Demir D, Gozeler M, Dalay N,. Microsatellite instability and methylation of the DNA mismatch repair genes in head and neck cancer. Ann Oncol 2006; 17: 995-999.
37. Kim DH, Nelson HH, Wiencke JK, et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001; 61: 3419-3424.
38. Laytragoon-Lewin N, Chen F, Castro J, et al. DNA content and methylation of p16, DAPK and RASSF1A gene in tumour and distant, normal mucosal tissue of head and neck squamous cell carcinoma patients. Anticancer Res 2010; 30: 4643-4648.
39. Schulz P, Scholz A, Rexin A, et al. Inducible re-expression of p16 in an orthotopic mouse model of pancreatic cancer inhibits lymphangiogenesis and lymphatic metastasis. Br J Cancer 2008; 99: 110-117.
40. Harada H, Nakagawa K, Iwata S, et al. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 1999; 59: 3783-3789.
41. Thomas GR, Nadiminti H, Regalado J,. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 2005; 86: 347-363.